Literature DB >> 342603

C57BL/10/CR mice: nonresponders to activation by the lipid a moiety of bacterial lipopolysaccharide.

K P McAdam, J L Ryan.   

Abstract

C57BL/10/CR mice do not respond to the lipid A moiety of LPS. This defect was demonstrated in vivo by a decreased production of the acute phase serum amyloid protein SAA. In addition, the defect was demonstrated in vitro by using cultures of spleen cells and peritoneal cells. No mitogenesis of spleen cells or enhanced glucose utilization by either spleen cells or peritoneal cells was observed when the cells were stimulated by lipid A or phenol-extracted Escherichia coli K235 LPS. The response of these mice to PHA, Con A, Poly I:C, 8BrcGMP, and butanol extraced E. coli K235 LPS was normal. Thus, the inability of lipid A to stimulate B lymphocyte mitogenesis and activate peritoneal cells in vitro may correlate with its inability to induce the acute phase SAA in vivo. B10/CR mice represent another strain, similar to the C3H/HeJ, which is nonresponsive to lipid A and should be useful in eludcidating the mechanism by which bacterial LPS activates cells.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 342603

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Filamentation by Escherichia coli subverts innate defenses during urinary tract infection.

Authors:  Sheryl S Justice; David A Hunstad; Patrick C Seed; Scott J Hultgren
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-15       Impact factor: 11.205

2.  Genetic basis for unresponsiveness to lipopolysaccharide in C57BL/10Cr mice.

Authors:  A Coutinho; T Meo
Journal:  Immunogenetics       Date:  1978-12       Impact factor: 2.846

3.  Urinary tract infection drives genome instability in uropathogenic Escherichia coli and necessitates translesion synthesis DNA polymerase IV for virulence.

Authors:  Damian Gawel; Patrick C Seed
Journal:  Virulence       Date:  2011-05-01       Impact factor: 5.882

4.  Purine Biosynthesis Metabolically Constrains Intracellular Survival of Uropathogenic Escherichia coli.

Authors:  Carrie L Shaffer; Ellisa W Zhang; Anne G Dudley; Beverly R E A Dixon; Kirsten R Guckes; Erin J Breland; Kyle A Floyd; Daniel P Casella; Holly M Scott Algood; Douglass B Clayton; Maria Hadjifrangiskou
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

5.  Biological and immunological properties of Coxiella burnetii vaccines in C57BL/10ScN endotoxin-nonresponder mice.

Authors:  J C Williams; J L Cantrell
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

6.  Some effects of the administration of endotoxin in mice. Specific cleavage of serum albumin by an acid protease and the generation of amyloid serum component.

Authors:  P D Gorevic; Y Levo; P C Chatpar; B Frangione; E C Franklin
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

7.  Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis.

Authors:  Sheryl S Justice; Chia Hung; Julie A Theriot; Daniel A Fletcher; Gregory G Anderson; Matthew J Footer; Scott J Hultgren
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-22       Impact factor: 11.205

8.  Lipopolysaccharides from Bacteroides fragilis are mitogenic for spleen cells from endotoxin responder and nonresponder mice.

Authors:  K A Joiner; K P McAdam; D L Kasper
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

9.  Characterization of a phase I Coxiella burnetii chloroform-methanol residue vaccine that induces active immunity against Q fever in C57BL/10 ScN mice.

Authors:  J C Williams; T A Damrow; D M Waag; K Amano
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

10.  Construction of a BALB/c congenic mouse, C.C3H-Lpsd, that expresses the Lpsd allele: analysis of chromosome 4 markers surrounding the Lps gene.

Authors:  S N Vogel; J S Wax; P Y Perera; C Padlan; M Potter; B A Mock
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.